Matches in SemOpenAlex for { <https://semopenalex.org/work/W2901477064> ?p ?o ?g. }
Showing items 1 to 43 of
43
with 100 items per page.
- W2901477064 abstract "A kemoterapias szerek farmakokinetikai parametereinek pontos monitorozasa elengedhetetlen, hiszen szamos mellekhatassal jarhatnak. Celkitűzes: Nagy dozisu methotrexatkezelesek farmakokinetikajanak es toxicitasanak vizsgalata akut lymphoid leukaemias gyermekekben. Betegek es modszerek: ALL-BFM 1995 es 2002 protokollok szerinti 5 g/m 2 /24 ora dozisu methotrexatkezelesre 43 gyermeknel (28 fiu, 15 lany, atlageletkor 7,03 ev) 147 esetben kerult sor. A methotrexat- es 7-hidroxi-methotrexat-szint-meghatarozast nagy nyomasu folyadekkromatografiaval vegeztek a szerzők az infuzio beadasat kovető 24., 36., 48. oraban. Vizsgaltak a fellepő maj- es vesetoxicitast, verkepet, a grade III/IV mucositis kialakulasat. Eredmenyek: A methotrexat koncentracioja az esetek 72,5%-aban a terapias tartomanyba (30–100 µmol/l) esett. Az ismetelt kezelesek hasonlo methotrexatszinteket eredmenyeztek. Hepatotoxicitas 17%-ban, hypoproteinaemia 48,9%-ban fordult elő a kezeleseket kovetően. Szignifikans korrelacio allt fent a 7-hidroxi-methotrexat- es a szerumkreatinin-szintek kozott (p 2 dozisu kezeleseket kovetően megbizhatoan lehetett a terapias szerumszinteket biztositani. A kialakult mellekhatasok enyhek es reverzibilisek voltak. A 7-hidroxi-methotrexat-szintek monitorozasa talan hasznosabb a methotrexatszintekenel. Orv. Hetil., 2011, 152, 1609–1617. | Monitoring the pharmacokinetic parameters of different anticancer drugs is necessary because they might have several side effects. Aim: Pharmacokinetic and toxicity evaluation of high-dose methotrexate treatments in children with acute lymphoblastic leukemia. Patients and methods: 43 children (28 boys, 15 girls, mean age: 7.03 years) in 147 cases were treated with 5 g/m 2 /24h MTX according to ALL-BFM 1995 and 2002 protocols. Methotrexate and 7-hydroxi-methotrexate levels were measured with high pressure liquid chromatography at 24, 36, 48 hours. Authors registered the development of hepatotoxicity, nephrotoxicity, grade III/IV oral mucositis. Results: Therapeutic methotrexate serum concentrations (30-100µmol/l) were achieved in 72.5% of the cases. Repeated treatments resulted similar serum levels. Hepatotoxicity and hypoproteinemia occurred in 17% and in 48.9% of the cases. There was significant correlation between serum 7-hydroxi-methotrexate and creatinine levels (p 2 methotrexate resulted reliable therapeutic serum levels with mild and reversible toxicity. 7-hydroxi-methotexate measurements might be more useful than methotrexate levels to detect toxicity. Orv. Hetil., 2011, 152, 1609–1617." @default.
- W2901477064 created "2018-11-29" @default.
- W2901477064 creator A5015282944 @default.
- W2901477064 creator A5017149421 @default.
- W2901477064 creator A5048329276 @default.
- W2901477064 creator A5053987717 @default.
- W2901477064 creator A5060483520 @default.
- W2901477064 creator A5083366475 @default.
- W2901477064 date "2011-01-01" @default.
- W2901477064 modified "2023-10-18" @default.
- W2901477064 title "Nagy dózisú methotrexatkezelések farmakokinetikai vizsgálata gyermekkori hematológiai malignitásokban = Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies" @default.
- W2901477064 hasPublicationYear "2011" @default.
- W2901477064 type Work @default.
- W2901477064 sameAs 2901477064 @default.
- W2901477064 citedByCount "0" @default.
- W2901477064 crossrefType "journal-article" @default.
- W2901477064 hasAuthorship W2901477064A5015282944 @default.
- W2901477064 hasAuthorship W2901477064A5017149421 @default.
- W2901477064 hasAuthorship W2901477064A5048329276 @default.
- W2901477064 hasAuthorship W2901477064A5053987717 @default.
- W2901477064 hasAuthorship W2901477064A5060483520 @default.
- W2901477064 hasAuthorship W2901477064A5083366475 @default.
- W2901477064 hasConcept C126322002 @default.
- W2901477064 hasConcept C2778496288 @default.
- W2901477064 hasConcept C2781059491 @default.
- W2901477064 hasConcept C29730261 @default.
- W2901477064 hasConcept C71924100 @default.
- W2901477064 hasConcept C90924648 @default.
- W2901477064 hasConceptScore W2901477064C126322002 @default.
- W2901477064 hasConceptScore W2901477064C2778496288 @default.
- W2901477064 hasConceptScore W2901477064C2781059491 @default.
- W2901477064 hasConceptScore W2901477064C29730261 @default.
- W2901477064 hasConceptScore W2901477064C71924100 @default.
- W2901477064 hasConceptScore W2901477064C90924648 @default.
- W2901477064 hasLocation W29014770641 @default.
- W2901477064 hasOpenAccess W2901477064 @default.
- W2901477064 hasPrimaryLocation W29014770641 @default.
- W2901477064 hasRelatedWork W1826081227 @default.
- W2901477064 hasRelatedWork W1905535546 @default.
- W2901477064 isParatext "false" @default.
- W2901477064 isRetracted "false" @default.
- W2901477064 magId "2901477064" @default.
- W2901477064 workType "article" @default.